Recent Updates
Recently added Catalysts
TEVA Neutral Sentiment

The following tables present revenues, expenses and profit for each segment for the years ended

Thursday, April 18, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Teva Pharmaceuticals has reported its revenues, expenses, and profits for 2023 across its various segments. The United States segment showed a notable revenue increase to $7,731 million with a corresponding rise in segment profit. However, R&D expenses have also increased, which could affect future profitability. The International Markets segment experienced a decline in profit compared to the previous year, indicating challenges in that area.
Price reaction · baseline $13.18 (2024-04-17 close) · hit after-hours · clean, no other TEVA news in the window
day 0 close · peak
-3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenues for the United States segment increased from $7,003M in 2022 to $7,731M in 2023.
  • Segment profit for the United States increased significantly to $2,394M in 2023 compared to $1,934M in 2022.

CONCERNS & RISKS

  • Expenses in R&D increased, leading to higher expenditures in the United States segment.
  • The International Markets segment saw a slight decline in segment profit from $538M in 2022 to $465M in 2023.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+92%
120-day peak, hindsight
Typical move
2.2%
average across 12 past catalysts
Lead asset
DR-5001
Phase 3 · Respiratory Tract Diseases

Full Press Release Details

The following tables present revenues, expenses and profit for each segment for the years ended December 31, 2023 and 2022, and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
United States Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Revenues $ 7,731 $ 7,003 $ 2,266 $ 1,896 $ 1,892 $ 1,677
Gross profit 4,310 3,734 1,444 1,060 1,017 789
R&D expenses 604 485 144 156 156 149
S&M expenses 938 879 238 243 250 207
G&A expenses 378 440 90 93 101 95
Other income ( 5 ) ( 3 ) ( 1 ) ( 2 ) ( 1 )
Segment profit* $ 2,394 $ 1,934 $ 974 $ 571 $ 511 $ 338
Europe Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Revenues $ 4,837 $ 4,525 $ 1,344 $ 1,146 $ 1,163 $ 1,184
Gross profit 2,726 2,700 783 648 640 655
R&D expenses 220 213 52 62 53 53
S&M expenses 767 748 203 184 194 187
G&A expenses 263 246 67 66 61 70
Other income ( 2 ) ( 3 ) ( 1 )
Segment profit* $ 1,478 $ 1,496 $ 461 $ 338 $ 334 $ 345
International Markets Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Revenues $ 2,351 $ 2,352 $ 601 $ 591 $ 578 $ 581
Gross profit 1,160 1,224 299 293 283 285
R&D expenses 104 119 24 30 23 27
S&M expenses 487 467 134 116 125 113
G&A expenses 142 154 37 33 34 38
Other income ( 39 ) ( 54 ) ( 4 ) ( 2 ) ( 31 ) ( 1 )
Segment profit* $ 465 $ 538 $ 109 $ 117 $ 132 $ 108
The following tables present revenues by major products and activities for each segment for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
United States Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 3,138 3,155 667 839 884 747
AJOVY 211 210 57 56 52 46
AUSTEDO 1,225 963 408 339 308 170
BENDEKA and TREANDA 237 309 52 56 67 62
COPAXONE 297 359 72 98 56 71
Anda 1,577 1,471 394 367 392 424
Other 1,047 536 616 142 131 158
Total $ 7,731 $ 7,003 $ 2,266 $ 1,896 $ 1,892 $ 1,677
Europe Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 3,664 3,466 938 886 909 932
AJOVY 160 124 45 41 39 36
COPAXONE 231 268 56 55 60 59
Respiratory products 265 273 70 61 66 68
Other 516 393 234 104 89 89
Total $ 4,837 $ 4,525 $ 1,344 $ 1,146 $ 1,163 $ 1,184
International markets Segment
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 1,932 1,980 506 470 478 477
AJOVY 63 42 19 18 14 13
COPAXONE 63 64 12 16 17 17
Other 293 266 64 87 69 74
Total $ 2,351 $ 2,352 $ 601 $ 591 $ 578 $ 581
The following tables present revenues by major products and activities for Canada for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:
Canada
Year ended December 31, Three months ended
2023 2022 December 31, September 30, June 30, March 31,
2023
(Unaudited, U.S.$ in millions)
Generic products 337 394 86 89 84 77
AJOVY 20 7 6 6 5 3
AUSTEDO - - - - - -
BENDEKA and TREANDA 4 7 1 1 1 1
COPAXONE 23 28 5 5 8 5
Anda - - - - - -
Other 9 13 1 4 1 2
Total $ 393 $ 449 $ 99 $ 106 $ 99 $ 89

Frequently Asked Questions

What were the 2023 revenues for the US Segment?

The US Segment had revenues of $7,731 million in 2023.

How much did R&D expenses increase in the US Segment?

R&D expenses in the US Segment rose to $604 million in 2023.

What was the profit for the Europe Segment in 2023?

The Europe Segment generated a profit of $1,478 million in 2023.

How did AJOVY sales perform in the US Segment?

AJOVY sales reached $211 million in the US Segment for 2023.

What were Canada's total revenues in 2023?

Canada recorded total revenues of $393 million in 2023.

ShareAdd on Google
Tags: TEVA Viatris Investor Conferences Healthcare pharmaceuticals revenue growth financial report 2023 earnings
Last updated: Apr 18, 2024

Biotech snapshot

Cash runway
$3655M liquidity · $0M/mo burn
Low dilution risk
Lead asset
DR-5001Phase 3
Respiratory Tract Diseases →

Catalyst track record

+92%
best trade around TEVA's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for TEVA.

See every catalyst's timing & PoA →